Acomplia Indications To Be Reviewed By Separate FDA Divisions, Sanofi Says

Sanofi-Aventis' weight loss/smoking cessation agent Acomplia (rimonabant) will be concurrently reviewed by two separate divisions within FDA's Office of New Drugs, Exec VP-Pharmaceutical Operations Hanspeter Spek said May 13 during the company's earnings call

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet